EASD 22: Efficacy of Ertugliflozin Across the Spectrum of EF in HF

Published: 19 Oct 2022

  • Views:

    Views Icon 122
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

EASD 22 — Dr Ambarish Pandey (UT Southwestern Medical Center, US) talks about the post-hoc analyses of VERTIS CV trial. 
In VERTIS CV, an SGLT2 inhibitor, ertugliflozin (Merck Sharp & Dohme LLC) reduced risk of hospitalization for heart failure compared with placebo. This post-hoc analyses investigated the efficacy of the treatment across the spectrum of ejection fractions (EF) in heart failure. 

1. What is the background of this analysis?
2. What was the study design and patient population?
3. What are the key findings and how are these compare to existing evidence?
4. What further research required?

Recorded remotely from Dallas, 2022.

Interviewer: Mirjam Boros
Videographer: Dan Brent